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Mycophenolate Mofetil (MMF) is a pro-drug of mycophenolic acid, which acts by inhibiting lymphocyte proliferation and 
antibody production. A number of reports have been published on its effectiveness in treating several dermatological 
conditions, including psoriasis, immunobullous diseases and connective-tissue disorders.
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 We report the use of MMF 
to treat chronic urticaria (CU). 
A 34-year-old white woman presented with a 3-month history of daily symptoms of CU. She had a family history of 
hypothyroidism, and was positive for thyroid peroxidase antibodies.  
Conventional combinations of high-dose H1 and H2 receptor antagonists for 6 months failed to control her 
symptoms. She was started on ciclosporin 3 mg/kg, with a good response within 3 weeks. This was reduced and 
stopped after 6 months, without relapse for 3 years. On subsequent flare, ciclosporin was prescribed, but although 
effective, this had to be discontinued because of nephrotoxicity. The condition responded to prednisolone 25 mg/day 
and MMF 500 mg twice daily. The MMF was gradually increased to a dose of 1.5 g twice daily, allowing the cessation 
of oral prednisolone. With this dose, the patient’s symptoms were well controlled for 6 months, but relapsed each time 
the dose was reduced below 500 mg twice daily, thus this dose was continued for a further 10 months. Fexofenadine 
180 mg daily was then re-introduced, which resulted in an improvement in symptoms that was sufficient to allow 
reduction and withdrawal of MMF without recurrence. She had no side-effects or laboratory abnormalities during 
treatment, and no recurrence of the CU had occurred during the 6-month follow-up after discontinuation of MMF. 
CU is characterized by the presence of recurrent pruritic weals for > 6 weeks. There is evidence that 40–50% of 
patients have some degree of autoimmunity, as shown by the finding of serological mediators such as autoantibodies 
against the high-affinity IgE receptor. This has prompted the use of immunomodulatory drugs in recalcitrant cases.
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The first-line treatment of CU is antihistamines. Patients not responding to oral antihistamines and combination 
therapy with leucotriene antagonists may need a more aggressive approach with short or prolonged courses of oral 
steroids or ciclosporin. Potential adverse effects can limit this regimen. 
MMF is a valuable treatment for patients who fail conventional treatment. Although the safety data for MMF within 
the dermatological literature is sparse, it has been used extensively within the field of organ transplantation, with a 
good safety profile. The potential adverse effects include gastrointestinal and haematological disturbances, and 
increased predisposition to infection.
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There have been no controlled studies investigating MMF in the treatment of CU. However, in an open-label trial of 
nine patients with CU who failed to respond to antihistamines and steroids, MMF 1 g twice daily for 12 weeks produced 
a significant decrease in the Urticarial Activity Score (P < 0.001), with the weal and itching scores reducing significantly 
(P < 0.004 and P < 0.002, respectively) after 6 weeks of treatment. All patients were able to stop prednisolone on 
completion of the study, and none had significant side-effects from MMF.
4
 Recently, a retrospective chart review of 19 
patients with autoimmune and idiopathic CU treated with MMF found that the treatment was helpful in improving both 
types of CU (91% vs. 88%) but that the rate of complete control was higher in the autoimmune group compared with 
the chronic idiopathic group (70% vs. 41%).
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Our results concur with those of previously published studies indicating that MMF is an effective and well-tolerated 
treatment option for CU that can lead to sustained remission. We found that combining MMF with oral prednisolone 
was helpful in gaining immediate control of the CU symptoms. Re-introduction of antihistamines after adequate 
disease control in our patient allowed withdrawal of MMF without recurrence of the CU. 
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